Schedule at a Glance
Tuesday, 12/7/2021 All times are CENTRAL Time

8:15 am - 10:45 am CT

General Session 1

10:45 am - 11:00 am CT  Break
11:00 am - 1:00 pm CT

COVID Update

Clinical Research Workshop

How to select biomarkers rationally
Justin Balko, PharmD, PhD
Vanderbilt University Medical Center
Nashville, TN

How to design an efficient clinical study
Valentina Nekljudova, PhD
German Breast Group
Neu-Isenburg, Germany

How to include patient advocates in clinical research
Patricia Spears, BS
University of North Carolina at Chapel Hill
Chapel Hill, NC

How to present clinical research results effectively
George W. Sledge, Jr, MD
Stanford University School of Medicine
Stanford, CA

Basic Science for Breast Oncologists Workshop

Genome editing in human organoids as new models for discovery
Jennifer Rosenbluth, MD, PhD
University of California, San Francisco
San Francisco, CA

In silico experimentation from your living room: Tools to access and analyze existing datasets
Daniel G. Stover, MD
Ohio State University Comprehensive Cancer Center
Columbus, OH

Tricking T cells into action: Using patient-derived organoids to identify and expand tumor-specific T cells
Senthil K. Muthuswamy, PhD
Beth Israel Deaconess Medical Center
Boston, MA

Meeting the bar: How to tell when basic science discoveries are ready to translate
Bora Lim, MD
Baylor College of Medicine
Houston, TX

10:00 am - 5:00 pm CT Exhibits
1:00 pm - 4:00 pm CT  Trust in Science and Healthcare
4:00 pm - 5:00 pm CT Brinker Award Lectures
5:00 pm - 7:00 pm CT

Updates on advances in key areas and in technologies available for translational research. Many of these sessions will provide attendees with a better understanding of the background leading up to talks they will hear in the succeeding days, and some of the techniques that will be used. These presentations should also provide researchers with ideas and techniques to be considered for their own studies.

Triple Positive Breast Cancer

The ideal partner to HER2 directed therapies
Sara A. Hurvitz, MD
Los Angeles, CA

ER/HER2+ cross talk
Charles M. Perou, PhD
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, NC

Escalating and de-escalation - titrating the right regimen in early stage HER2 positive
Nadia Harbeck, MD, PhD
University of Munich
Munich, Germany

Artificial Intelligence: Beyond the Soundbites

Everything you always wanted to know about AI but were afraid to ask
Regina Barzilay, PhD
Cambridge, MA

Artificial intelligence: Guiding the pathologists' eyes
Thomas J. Fuchs
Memorial Sloan Kettering Cancer Center
New York, NY

Artificial intelligence in radiology

Refining Heredity Risk

Reclassifying VUS: New techniques can solve the puzzle once and for all
Sean V. Tavtigian, PhD
Huntsman Cancer Institute at the University of Utah
Salt Lake City, UT

Clinical management of moderate penetrance genes
Allison W. Kurian, MBBS, MD, MSc
Stanford University School of Medicine
Palo Alto, CA

Polygenic risk score: Should clinicians use it
Montserrat García-Closas, MD, DrPH
National Cancer Institute
Rockville, MD

Panel Discussion

Evidence Based Integrative Therapies - During and Beyond Treatment

Ting Bao, MD, DABMA, MS
Memorial Sloan Kettering Cancer Center
New York, NY

Hypnosis and mindfulness
David Spiegel, MD
Stanford University
Stanford, CA

Complementary treatments
Donald Abrams, MD
University of California, San Francisco
San Francisco, CA

What does diet and exercise change really do for you
Nicole Simone, MD
Thomas Jefferson University
Philadelphia, PA

Panel Discussion

7:30 pm - 10:00 pm CT OPEN SATELLITE EVENTS

Wednesday, 12/8/2021
7:00 am - 8:30 am

Poster Session 1

7:00 am - 8:30 am  Spotlight Poster Discussion Sessions 1-3

1. Endocrine Resistance: Novel mechanisms and emerging new therapies
2. Insights to CDK4/6i resistance: Novel models and clinical/translational genomics
3. Targets in Triple Negative Breast Cancer

8:45 am - 11:30 am CT GENERAL SESSION 2
10:00 am - 5:00 pm CT EXHIBITS 
12:00 pm - 1:00 pm CT


12:00 pm - 2:00 pm CT SPECIAL SESSIONS

1. Re-framing Leadership in Academic Breast Oncology Post COVID-19
2. Regulatory Insights to the 2021 Early Stage Breast Cancer Approvals
3. Health Equity in Translational Research Studies
2:00 pm - 3:00 pm CT


Translational Forum: ER mutations and SERDS

Next generation sequencing in ER targets
Donald P. McDonnell, PhD
Duke University School of Medicine
Durham, NC

ER+ word salad decoded: SERD, SERM, SERCA, CERAN, PROTAC
Komal Jhaveri, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Basic Science Forum: Targeting Nuclear Steroid Receptors

A new perspective on androgen receptor action in estrogen receptor-α positive breast cancer
Wayne Tilley
The University of Adelaide
Adelaide, Australia

Christy R. Hagan, PhD
University of Kansas Medical Center
Kansas City, KS

Suzanne Conzen, MD
UT Southwestern Medical Center
Dallas, TX

Clinical Case Discussion

3:00 pm - 5:00 pm CT


Triple Negative Breast Cancer: Critical Update on Biology and Management

Genomic and transcriptomic landscape of TNBC
Zhi-Ming Shao, MD
Fudan University of Shanghai
Shanghai, China

Optimizing the management of early stage TNBC
Elizabeth A. Mittendorf, MD, PhD
Dana-Farber Brigham and Women's Cancer Center
Boston, MA

Management of special subtypes of TNBC
Alexandra Thomas, MD, FACP
Wake Forest Baptist Health
Winston-Salem, NC

Emerging Adjuvant Therapies: What's Ready for Prime Time?

Approving new therapies
Suparna Wedam, MD
Food and Drug Administration
Silver Spring, MD

CDK4/6 for ER+
Ingrid A. Mayer, MD, MSCI
Vanderbilt-Ingram Cancer Center
Nashville, TN

IO vs Capecitabine for TNBC
Sherene Loi, MD, PhD
Pater MacCallum Cancer Centre
Melbourne, Australia

PARP for BRCA+ breast cancers
Andrew Tutt, MD
Institute of Cancer Research
London, United Kingdom

Fine Tuning Risk Assessment and Risk Reduction

Lifestyle: Exercise and diet
Neil M. Iyengar, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Emergent pharmacologic interventions for prevention: Non endocrine treatments
Brandy Heckman, PhD, MPH
National Cancer Institute
Rockville, MD

Constance Lehman, MD, PhD
Massachusetts General Hospital
Boston, MI

Panel Discussion

Local Therapy - Management of the Axilla
presented by SABCS with the Society of Surgical Oncology

Axillary management in upfront surgery - staging, local control or both?
Stephanie Wong, MD, MPH
McGill University
Montreal Canada

Refining axillary management after neoadjuvant chemotherapy - what does the evidence support
Eleftherios (Terry) Mamounas, MD, MPH, FACS
Orlando Health Cancer Institute
Orlando, FL

Can radiation replace ALND after + SLNB
Reshma Jagsi, MD, DPhil
University of Michigan
Ann Arbor, MI

Options for reducing risk for lymphedema when ALND/regional nodal XRT are needed
Hani Sbitany, MD
Mount Sinai
New York, NY

5:00 pm - 6:30 pm CT Poster Session 2
5:00 pm - 6:30 pm CT Spotlight Sessions 4-6
4. Brain Metastases: Managing LMD/Targeting HER2
5. Life after breast cancer: Cardiac health, fertility preservation, and returning to life
6. Genomic and Genetic Analysis on Metastases
7:30 pm - 10:00 pm CT OPEN SATELLITE EVENTS

Thursday, 12/9/2021

7:00 am - 8:30 am CT

Poster Session 3

7:00 am - 8:30 am CT Spotlight Poster Discussion Sessions
7. Locoregional Treatment: De-Escalation in Breast Cancer
8. Novel Therapies for HER2+ Disease
9. Evaluating Emerging and Established Biomarkers
8:45 am - 11:30 am CT GENERAL SESSION 3 
10:00 am - 5:00 pm CT  EXHIBITS
11:30 am - 12:30 pm CT 


One Week of Whole Breast RT is the New Standard of Care

Charlotte E. Coles, PhD
University of Cambridge
Cambridge, United Kingdom
Julia White, MD
The Ohio State University
Columbus, OH

12:30 pm - 1:00 pm CT AACR Distinguished Lectureship in Breast Cancer Research
1:30 pm - 2:00 pm CT


Genomic Profiling in Early Stage ER Positive Breast Cancers/Precision Medicine
Mitchell Dowsett, PhD
Royal Marsden Hospital
London, United Kingdom

2:00 pm - 3:00 pm CT


Translational Forum: HER2 Heterogeneity

Kim RM Blenman, PhD
Yale Cancer Center
Yale University
New Haven, CT

Heterogeneity in treatment outcomes for HER2+ breast cancer - clinical management strategies
Sara M. Tolaney, MD, MPH
Dana Farber Cancer Institute
Boston, MA

Molecular heterogeneity in HER2+ breast cancer - can outcomes be predicted?
Aleix Prat, MD, PhD
Hospital Clinic Barcelona
Barcelona, Spain

Clinical Forum: The Promise and Reality of Oligometastatic Ablation for Breast Cancer

Oligometastatic disease: Definitions and practice patterns
Yolande Lievens, MD, PhD
UZ Gent
Ghent, Belgium

OMD data and gaps in breast cancer
David Palma, MD, PhD
London Health Sciences Center
Ontario, Canada

Molecular Tumor Board

3:00 pm - 5:00 pm CT 

Educational Sessions

Local Therapy of the Primary and Beyond in Patients with Advanced Disease

Local therapy of the primary tumor
Seema Khan, MD
Northwestern University
Chicago, IL

Special indications where local therapy should be considered
Anthony Lucci, MD
UT MD Anderson Cancer Center
Houston, TX

Oligo-progressive disease. Treating locally more than systemically
Amy Xu, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Clinical Updates on Immunotherapy

Immunotherapy in the metastatic setting - chemo backbone and biomarker
Rebecca Dent, MD
National Cancer Center

Immune therapy in the (neo) adjuvant setting
Heather L. McArthur, MD, MPH
Cedars-Sinai Medical Center
Los Angeles, CA

IO beyond TNBC
Giuseppe Curigliano, MD, PhD
European Institute of Oncology
Milan, Italy

Anti-Cancer Immune Response

Understanding the anti-cancer immune response: Innate and adaptive responses to cancer cells
Laurence Zitvogel, MD, PhD
Institut Gustave Roussy
Villejuif, France

Micro and macro: Macrophage and microbiome diversity in the breast cancer microenvironment
Jennifer L. Guerriero, PhD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, MA

Optimizing immunotherapy efficacy in the clinic through biomarkers: Advances in single cell and spatial histology analyse
Marleen Kok, MD, PhD
The Netherlands Cancer Institute
Amsterdam, Netherlands

The Fluid Landscape of Liquid Biopsy

Monitoring of advanced breast cancer with liquid biopsies
François-Clément Bidard, MD, PhD
Institut Curie
Paris Saclay University
Paris, France

Single cell analysis of circulating tumor cells
Shyamala Maheswaran, PhD
Massachusetts General Hospital
Boston, MA

Challenges in early detection - screening and MRD
Pedram Razavi, MD, PhD
Memorial Sloan Kettering Cancer Center
New York, NY

Targeting the "Un-druggable"

Targeting EZH2 functions
Celina G. Kleer, MD
University of Michigan Medical School
Ann Arbor, MI

RNA metabolism and splicing
Trey Westbrook, PhD
Baylor College of Medicine
Houston, TX

Novel epigenomic targets in TNBC
David W. Cescon, MD, PhD
Princess Margaret Cancer Centre
Toronto, Canada

5:00 pm - 6:30 pm CT Poster Session 4

Spotlight Poster Discussion Sessions
10. Novel Immunotherapy Approaches
11. The Future is Now: Innovation in Pathology and Radiology
12. Disparities: Social Determinants of Health and Interventions
 7:30 pm - 10:00 pm CT

Friday, 12/10/2021

7:00 am - 8:30 am CT



13. Novel Therapeutics
14. Clinical Translational Updates in Invasive Lobular Carcinoma
15. Defining Molecular Markers of Endocrine Resistance in Clinic

8:45 am - 11:30 pm CT GENERAL SESSION 4
10:00 am - 5:00 pm CT EXHIBITS
11:30 am - 12:30 pm CT


RxPONDER: Was it all OFS?

Michael Gnant, MD
Medical University of Vienna
Vienna, Austria

Sibylle Loibl, Dr Med
GBG Forschungs GMBH
Hessen, Germany

12:30 pm - 1:00 pm CT AACR Outstanding Investigator Award for Breast Cancer Research
1:00 pm - 1:30 pm CT  Break
1:30 pm - 2:00 pm CT


Triple Negative Breast Cancer - Pitfalls and Progress
Lisa A. Carey, MD, ScM, FASCO
University of North Carolina at Chapel Hill
Chapel Hill, NC

2:00 pm - 3:00 pm 


DNA Repair in Breast Cancer - Diagnosis and Treatment

CRISPR screens to identify novel DNA repair defects synthetic lethal therapies
Daniel Durocher, PhD
Lunefeld-Tanenbaum Research Institute
Toronto, Canada

Genomics of DNA repair defects in breast cancer
Serena Nik-Zainal, PhD
University of Cambridge
Cambridge, United Kingdom

Targeting DNA damage response and HRD in breast cancer
Timothy A. Yap, MBBS, PhD, FRCP
UT MD Anderson Cancer Center
Houston, TX

The Evolution of Local Therapy in the Genomic Era

Is less (or more) axillary surgery needed in the genomic era?
Monica Morrow, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Can genomic risk be used to tailor radiation therapy?
Philip Poortmans, PhD
Iridium Netwerk
Paris, France

3:00 pm - 5:00 pm CT

Year in Review

Basic science
Xiang Zhang, PhD
Baylor College of Medicine
Houston, TX

Translational research
Christina Curtis
Stanford Medicine
Stanford, CA

Early breast cancer
Foluso Ademuyiwa, MD
Washington University School of Medicine
St. Louis, MO

Advanced breast cancer
Peter Schmid, MD, PhD
Bart's Cancer Institute Queen Mary University of London
London, United Kingdom

5:00 pm - 7:00 pm CT View from the Trenches: What will You do on Monday Morning
 7:30 pm - 10:00 pm CT OPEN SATELLITE EVENT
12:00 pm - 1:45 pm